–Toripalimab continues to demonstrate synergy as the cornerstone in innovative combination therapies Read More See also PACS Group, Inc. Announces Closing of Its Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares from the Selling Stockholders
